Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period

BACKGROUND: Interleukin-23 inhibitors are novel treatment options for psoriasis, and their efficacy and safety have been widely demonstrated in phase 3 clinical trials. Nonetheless, their real-world data remain limited, especially in Asia. OBJECTIVE: To evaluate the real-world effectiveness of inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Yung, Tong, Bik Sai Bessie, Ngan, Pui Yan, Au, Chi Sum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179803/
https://www.ncbi.nlm.nih.gov/pubmed/34104632
http://dx.doi.org/10.2147/PTT.S312109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179803/
https://www.ncbi.nlm.nih.gov/pubmed/34104632
http://dx.doi.org/10.2147/PTT.S312109

Ejemplares similares